Open AccessSerum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
Author(s) -
JODO S.,
KOBAYASHI S.,
KAYAGAKI N.,
OGURA N.,
FENG Y.,
AMASAKI Y.,
FUJISAKU A.,
AZUMA M.,
YAGITA H.,
OKUMURA K.,
KOIKE T.
Publication year - 1997
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1997.d01-901.x
Subject(s) - medicine , immunology , autoimmune disease , fas receptor , disease , lupus erythematosus , antibody , apoptosis , biology , biochemistry , programmed cell death
There are two major forms of the Fas molecule, membranous Fas and soluble Fas (sFas). To clarify the clinical significance of sFas in autoimmune diseases, we designed a sandwich ELISA to determine serum concentrations of sFas and its molecular structure, and we then analysed the correlation between levels of sFas and laboratory findings in patients with SLE and other autoimmune diseases. The levels of serum sFas were significantly higher in SLE patients than in subjects with other autoimmune diseases and in healthy donors, and the frequency of a positive serum sFas was much greater in SLE patients with high SLE disease activity index scores than in those with low scores. In addition, sFas‐positive SLE patients showed a significant difference in various laboratory parameters from sFas‐negative SLE patients. Serial measurements of serum sFas levels in SLE patients with active disease revealed that the elevated level of sFas dramatically decreased with improvement in clinical and laboratory findings, following corticosteroid therapy. We propose that the serum level of sFas can serve as an appropriate marker for evaluating SLE disease activity. Serum sFas is heterogeneous with respect to molecular structure, thus several mechanisms are involved in the generation of sFas.